Poolbeg Pharma PLC

Immunomodulator II patent granted in Japan Further enhancement of the patent portfolio

By Elric Langton | 21 November 2023

I and Alex have a financial interest in Poolbeg Pharma.

In a move that could leave competitors choking on their sushi, Poolbeg Pharma, the nimble biopharmaceutical maverick, has just had it is Immunomodulator II patent application given the nod by the Japanese Patent Office. This marks yet another feather in Poolbeg's cap. This company seems to have a knack for navigating the labyrinthine world of intellectual property with the agility of a cat on a hot tin roof.

The patent in question zeroes in on the pharmaceutical composition of POLB 001, a potential game-changer in treating severe influenza for hospitalised patients, to be used with antiviral compounds. This development doesn't just add a layer of protection for Poolbeg's intellectual property in Japan; it's akin to building a fortress.

But wait, there's more. Poolbeg, not resting on its laurels, had previously announced the full granting of the 'Immunomodulator I' patent by the Japanese Patent Office in September 2023. This one-two punch of patent approvals in Japan cements the company's position as a heavyweight in the flu treatment arena.